跳转至内容
Merck
CN

382170

组蛋白去乙酰化酶抑制剂IV

The Histone Deacetylase Inhibitor IV, also referenced under CAS 537034-15-4, controls the biological activity of Histone Deacetylase. This small molecule/inhibitor is primarily used for Cell Structure applications.

别名:

组蛋白去乙酰化酶抑制剂IV

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C19H23N3O2
化学文摘社编号:
分子量:
325.40
UNSPSC Code:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

组蛋白去乙酰化酶抑制剂IV, The Histone Deacetylase Inhibitor IV, also referenced under CAS 537034-15-4, controls the biological activity of Histone Deacetylase. This small molecule/inhibitor is primarily used for Cell Structure applications.

InChI key

ZAIULUYKQLVQFH-UHFFFAOYSA-N

InChI

1S/C19H23N3O2/c20-16-11-7-8-12-17(16)22-19(24)14-6-2-5-13-18(23)21-15-9-3-1-4-10-15/h1,3-4,7-12H,2,5-6,13-14,20H2,(H,21,23)(H,22,24)

assay

≥97% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

beige

solubility

DMSO: 100 mg/mL
methanol: 5 mg/mL

shipped in

ambient

storage temp.

−20°C

Quality Level

Biochem/physiol Actions

主要靶标
组蛋白脱乙酰酶
产物不与ATP竞争。
可逆:否
细胞可渗透性:是

Disclaimer

毒性:有害(C)

General description

一种作为FXN-(frataxin基因)特异性HDAC(组蛋白脱乙酰酶)抑制剂的细胞渗透性庚二酰苯胺化合物。由于组蛋白H3和H4的低乙酰化作用,通过增加H3K14、H4K5和H4K12处的乙酰化作用,逆转了FRDA(Friedreich′s共济失调)细胞中FXN转录的沉默(在初级FRDA淋巴细胞中,FXN mRNA在5 µM时增加约3倍,在2.5 µM时FRDA细胞系中frataxin表达约3倍),而在H3K9、H4K8和H4K16处的乙酰化作用没有明显变化。相比之下,另外两种常用的HDAC抑制剂曲古抑菌素-A(目录编号 647925647926)和SAHA对FXN转录没有作用。

Other Notes

Herman, D., et al. 2006.Nat. Chem. Biol.2, 551.

Packaging

用惰性气体包装

Preparation Note

复溶后,等分并冷冻保存(-20°C)。储备溶液在-20°C下可稳定保存至多6个月。

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持